These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35170228)

  • 1. Effect of food on capsule and granule formulations of selumetinib.
    Cohen-Rabbie S; Mattinson A; So K; Wang N; Goldwater R
    Clin Transl Sci; 2022 Apr; 15(4):878-888. PubMed ID: 35170228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I, Open-label, Randomized, Crossover Study of the Relative Bioavailability of Capsule and Granule Formulations of Selumetinib.
    Cohen-Rabbie S; Mattinson A; So K; Wang N; Goldwater R
    Clin Ther; 2022 Apr; 44(4):565-576. PubMed ID: 35410754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects.
    Tomkinson H; McBride E; Martin P; Lisbon E; Dymond AW; Cantarini M; So K; Holt D
    Clin Ther; 2017 Nov; 39(11):2260-2275.e1. PubMed ID: 28985960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Population Pharmacokinetic Assessment of the Effect of Food on Selumetinib in Patients with Neurofibromatosis Type 1-Related Plexiform Neurofibromas and Healthy Volunteers.
    Zuo P; Arefayene M; Pan WJ; Freshwater T; Monteleone J
    Clin Pharmacol Drug Dev; 2024 Jul; 13(7):770-781. PubMed ID: 38591154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.
    Schalkwijk S; Zhou L; Cohen-Rabbie S; Jain L; Freshwater T; So K; He Z; Gioni I; Tomkinson H; Vishwanathan K; Zhou D
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):189-202. PubMed ID: 33903938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
    Kinzler ER; Pantaleon C; Iverson M; Aigner S
    Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1).
    Aslanis V; Abd-Elaziz K; Slack RJ; Brinch A; Gravelle L; Morley W; Phung D; Herman K; Holyer I; Poulsen KK; Dogterom P; Tantawi S; Zetterberg FR; Jacoby B; Schambye H; Lindmark B
    Cancer Chemother Pharmacol; 2024 Nov; 94(5):707-720. PubMed ID: 39167148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects.
    Chen JJ; Hewitt LA
    Drugs R D; 2018 Mar; 18(1):77-86. PubMed ID: 29392574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Food (Low and High Fat) on Pharmacokinetics of FCN-159, a Selective MEK Inhibitor, in Healthy Chinese Males.
    Li J; Tan Y; Li K; Hui AM; Wu Z; Han P; Wei Z; Qiu J; Diao L; Wang X
    Adv Ther; 2023 Mar; 40(3):1074-1086. PubMed ID: 36627544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
    Leijen S; Soetekouw PM; Jeffry Evans TR; Nicolson M; Schellens JH; Learoyd M; Grinsted L; Zazulina V; Pwint T; Middleton M
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1619-28. PubMed ID: 21953275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers.
    Rioux N; Kim A; Nix D; Bowser T; Warmuth M; Smith PG; Schindler J
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):91-96. PubMed ID: 30368584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects.
    Lindsay J; Mudge S; Thompson GR
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.
    Haroldsen PE; Musson DG; Hanson B; Quartel A; O'Neill CA
    Clin Ther; 2015 Jul; 37(7):1555-63. PubMed ID: 26101174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.
    Dean E; Banerji U; Schellens JHM; Krebs MG; Jimenez B; van Brummelen E; Bailey C; Casson E; Cripps D; Cullberg M; Evans S; Foxley A; Lindemann J; Rugman P; Taylor N; Turner G; Yates J; Lawrence P
    Cancer Chemother Pharmacol; 2018 May; 81(5):873-883. PubMed ID: 29541803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
    Shumaker R; Aluri J; Fan J; Martinez G; Ren M; Chen K
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):284-91. PubMed ID: 24548978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability and Pharmacokinetics of TRPV1 Antagonist Mavatrep (JNJ-39439335) Tablet and Capsule Formulations in Healthy Men: Two Open-Label, Crossover, Single-Dose Phase 1 Studies.
    Manitpisitkul P; Shalayda K; Russell L; Sanga P; Williams Y; Solanki B; Caruso J; Moyer JA
    Clin Pharmacol Drug Dev; 2018 Sep; 7(7):699-711. PubMed ID: 29125700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative bioavailability and food effect study of an oral suspension of alectinib in healthy volunteers using venipuncture and capillary microsampling.
    Liu SN; Agarwal P; Heinig K; Datye A; Sturm-Pellanda C; Crugnola A; Arca M; Miles D
    Clin Transl Sci; 2023 Jun; 16(6):1085-1096. PubMed ID: 36978270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a High-fat Meal on the Pharmacokinetics of the VEGFR Inhibitor Fruquintinib: A Randomized Phase I Study in Healthy Subjects.
    Qian H; Fan S; Li K; Sai Y; Su W; Chen Q; Liu Y; Li T; Wang W; Jia J; Yu C; Liu Y
    Clin Ther; 2019 Aug; 41(8):1537-1544. PubMed ID: 31272709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.